Abstract:Abstract Background Current guidelines include fecal microbiota transplantation (FMT) in the management of recurrent Clostridioides difficile infections (CDI). However, FMT protocols are often facility dependent, and one variable is whether proton pump inhibitors (PPI) are given during preparation. Theoretically, PPIs reduce acidity and protects the transplanted microbiome for the most potent dose. On the other hand, PPIs have also been shown to negatively alter the microbiome and increase the risk of CDI. We conducted a systematic review of the literature to study PPI use on the efficacy of FMT delivered by the trans-oral route. Methods We searched PubMed/Medline, Cochrane Library, Embase, Scopus, and Web of Science through December 16th, 2018 using variations of keywords “fecal microbiota transplant” and “Clostridium difficile infection” with 4210 results. Two independent authors reviewed and excluded studies with unrelated topics, abstracts, case reports, or a low level of evidence. Studies with data on trans-oral FMT, PPI use, and the success rate were included. Final review yielded 11 studies including randomized controlled, case–control, cohort, retrospective and prospective trials. The primary outcome was the rate of FMT failure, defined as recurrence of symptoms with positive CDI testing at follow-up. Results Out of 233 included patients, 131 received a PPI per FMT protocol resulting in 27 cases of treatment failure. There were 23 cases of recurrence out of 102 patients who did not receive pre-FMT PPI. The primary outcome occurred in 20.6% in the group with PPI use vs. 22.6% in the group without (RR 0.91; CI 0.56 - 1.50). Limitations include the lack of studies directly comparing outcomes with respect to PPI use, and inability to control possible confounders such as chronic PPI use, amount of stool transplanted, and pre-FMT antibiotics. Conclusion We did not find a significant difference in efficacy between FMT protocols with regard to PPI use. It is possible that the theoretical benefit from increased survival of transplanted microbiota is offset by negative effects associated with PPIs. We suggest that routine use of PPIs in FMT be reconsidered in the absence of clear benefit. Further investigation is needed to optimize protocols for safety and efficacy. Disclosures All authors: No reported disclosures.

Proton Pump Inhibitor-Induced Gut Dysbiosis Increases Mortality Rates for Patients with Clostridioides difficile Infection

The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H2 Receptor Antagonists with Clinical Complications in Patients with Severe Sepsis

[Effects of Proton Pump Inhibitors on In-Stent Restenosis in Patients Receiving Clopidogrel: a Retrospective Analysis].

The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection

Hospitalized Patients on Proton Pump Inhibitors for Stress Ulcer Prophylaxis Have a Higher Risk of Clostridioides difficile Infection Compared to Those on Histamine-2 Receptor Antagonists

Association between reduced risk of gastrointestinal bleeding related to proton pump inhibitor use and subsequent all-cause death in patients with percutaneous coronary intervention

Timely Cessation of Proton Pump Inhibitors in Critically Ill Patients Impacts Morbidity and Mortality: A Propensity Score-Matched Cohort Study*

Association Between Risk of Clostridium difficile Infection and Duration of Proton Pump Inhibitor or H2-Receptor Antagonist Use in Hospitalized Patients

The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence

2434. Proton Pump Inhibitor Use on Efficacy of Fecal Microbiota Transplant Administered by Trans-Oral Routes for Clostridioides Difficile Infection: A Systematic Review and Analysis

Pump the Breaks on the Slide to Harm From Nonindicated Proton Pump Inhibitors After Critical Illness!*

Risk Factors for Clostridium Difficile Infection in Cirrhotic Patients.

Current situation of progress in long-term use of proton pump inhibitors may increase the risk of dementia

Proton Pump Inhibitor Therapy Does Not Affect Prognosis of Cirrhosis Patients with Acute Decompensation and Acute-on-Chronic Liver Failure: A Single-Center Prospective Study.

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota

Proton pump inhibitors increase the risk of carbapenem-resistant Enterobacteriaceae colonization by facilitating the transfer of antibiotic resistance genes among bacteria in the gut microbiome

Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics

High Incidence and Morbidity of Clostridium Difficile Infection among Hospitalized Patients with Inflammatory Bowel Disease: A Prospective Observational Cohort Study

Understanding the health risks and emerging concerns associated with the use of long-term proton pump inhibitors

Protective Effect of Pediococcus Pentosaceus LI05 Against Clostridium Difficile Infection in a Mouse Model.

Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study